Colleen Kelley, MD, MPH

Faculty member in the Division of Infectious Diseases with a secondary appointment in the Department of Epidemiology, Rollins School of Public Health, Emory University

Principal investigator on the PURPOSE 2 trial

Articles by Colleen Kelley, MD, MPH

Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH

ByJulia Bonavitacola,Colleen Kelley, MD, MPH

June 20th 2025

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.

Colleen Kelley, MD, MPH

Articles by Colleen Kelley, MD, MPH

Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH

Latest Updated Articles

Trending on AJMC

Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD

FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause

GLP-1 Receptor Agonists May Improve Rheumatoid Arthritis Symptoms

Elinzanetant Shows Strong 52-Week Safety for Vasomotor Symptoms: James Simon, MD

Low Trial Enrollment, Racial Disparities Limit Breast Cancer Treatment Innovation